Clinical Trials Logo

Filter by:
NCT ID: NCT00697931 Completed - Hepatitis B Clinical Trials

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Start date: May 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the immunogenicity and reactogenicity of the adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B when both are injected according to a three dose schedule (0, 1, 6 months) in an adult non-responder population

NCT ID: NCT00697853 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Start date: November 1998
Phase: Phase 2
Study type: Interventional

This study is undertaken to assess the immune response and safety profile of 4 lots of the novel adjuvanted hepatitis B vaccine that were formulated following different processes, with Engerix™-B as the control vaccine

NCT ID: NCT00697567 Completed - Clinical trials for Prophylaxis Herpes Simplex

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Start date: September 1992
Phase: Phase 2
Study type: Interventional

The purpose of the phase IIa study in healthy HSV seropositive and HSV seronegative adults is to evaluate the immunogenicity, reactogenicity and safety of herpes simplex (gD) candidate vaccine with or without adjuvant administered according to a 0, 1, 6 month schedule.

NCT ID: NCT00697242 Completed - Hepatitis B Clinical Trials

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Start date: January 1994
Phase: Phase 3
Study type: Interventional

In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects

NCT ID: NCT00697229 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Start date: September 1992
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, immunogenicity and reactogenicity of MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following two different schedules: 0, 2 months and 0, 6 months

NCT ID: NCT00697216 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Start date: March 1997
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and immunogenicity of the candidate HBV-MPL vaccine administered to healthy adults aged from 15 to 40 years, according to a 0, 6- month vaccination schedule, with Engerix™-B as control administered at 0, 1, 6 months.

NCT ID: NCT00697125 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Start date: June 1993
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

NCT ID: NCT00697086 Completed - Atrial Fibrillation Clinical Trials

European Study of Dronedarone in Atrial Fibrillation

ERATO
Start date: August 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of dronedarone for the control of ventricular rate at rest and during exercise in patients with atrial fibrillation (AF) and to assess the tolerability of dronedarone in the target population.

NCT ID: NCT00696891 Completed - Hepatitis B Clinical Trials

Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

Start date: June 1997
Phase: Phase 3
Study type: Interventional

This study is conducted to compare the immunogenicity, reactogenicity and safety of Engerix™-B and HBV-MPL vaccine against hepatitis B infection in an elderly population

NCT ID: NCT00696332 Completed - ALS Clinical Trials

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

ALS
Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.